Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
Summary
Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this week. The biotech is part of a growing group of companies developing therapies that
From the publisher
Headline and excerpt are shown for attribution. Full text remains with the publisher.
Related coverage
Another Option for Rare Benign Soft-Tissue Tumor Wins FDA Approval
(MedPage Today) -- The FDA approved the small-molecule inhibitor pimicotinib (Pimjetmi) for selected patients with symptomatic tenosynovial giant cell tumor (TGCT) and high surgical risk. An oral selective inhibitor of colony stimulating factor...
New Medicare Payment Model for Back Pain, Heart Failure Riles Docs
Physician groups are seeking a delay for a new Medicare demonstration model. The model debuts January 1 and requires doctors treating low back pain and congestive heart failure to meet performance standards or face payment penalties. That means those physicians could see payment consequences tied to the standards if the model starts on schedule.
Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs
Hims & Hers struck a deal with Eli Lilly to offer the drugmaker’s branded obesity treatments through its online health and wellness platform.
The process
How this works
- 1
Send the form
Name, email, and what you need. One request, one channel.
- 2
We route it
A vetted independent partner for this channel receives it. No one else does.
- 3
You get a reply
Within one business day, at no cost and with no obligation.
One partner per channel. Your details are never sold, and no partner sees another partner's requests.
The weekly brief
Get the weekly brief
One email a week with the stories that moved this field, plus what to watch next.
- One email a week, with the Monday refresh.
- Stories first — at most one labelled note, usually our own.
Fields marked * are required.